UroGen Pharma Ltd. Ordinary Shares (URGN)
Stock · NASDAQ · Health Care
$34.53as of 10/16/2026
Price chart
Active signals
URGN Signal Track Record
How signals performed across all stocks →What URGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +1.6% | 52% | October 8, 2026 |
| Bollinger Band Breakout | 24 | +11.6% | 67% | August 5, 2026 |
| Bollinger Band BreakdownActive now | 20 | +3.0% | 65% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +3.3% | 50% | March 11, 2026 |
| Any 20-session window (baseline) | +0.3% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a su…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 300
- Website
- www.urogen.com/
Fundamentals
- 1-day range
- $34.26$36.91
- Market cap
- $2.22B
- P/E (trailing)
- —
- P/E (forward)
- 13.36
- EPS (trailing)
- $-1.98
- Dividend yield
- —
- Beta
- 1.56
- Avg. volume
- 879.5K
How UroGen Pharma Ltd. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
UroGen Pharma Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Here's Why You Should Add URGN Stock to Your Portfolio NowYahoo · 9/30/2026
- UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales BaseYahoo · 9/25/2026
- Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?Yahoo · 9/23/2026
- Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?Yahoo · 9/23/2026
Insider Activity
Insider Actions →- Chris Degnan · October 8, 2026 · Option Exercise4.5K
- Chris Degnan · October 8, 2026 · Sale2.2K @ $36.69
- Mark Schoenberg · September 8, 2026 · Sale871 @ $42.92
- Jason Drew Smith · September 8, 2026 · Sale1.5K @ $42.54
- Mark Schoenberg · September 7, 2026 · Option Exercise1.7K
- Jason Drew Smith · September 7, 2026 · Option Exercise3.3K
- James A. Robinson Jr. · August 26, 2026 · Option Exercise2.0K
- Mark Schoenberg · August 20, 2026 · Sale60.7K @ $47.05
- Mark Schoenberg · July 9, 2026 · Sale10.0K @ $40
- Mark Schoenberg · June 22, 2026 · Sale10.0K @ $35.01
- Daniel George Wildman · June 22, 2026 · Grant8.0K
- Daniel George Wildman · June 22, 2026 · Grant10.0K
- James A. Robinson Jr. · June 22, 2026 · Grant8.0K
- James A. Robinson Jr. · June 22, 2026 · Grant10.0K
- Stuart Holden · June 22, 2026 · Grant20.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock
UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.